First-Line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients

Figure 1

Consort diagram: GC regimen: gemcitabine 1,200 mg/m²  (d1, d8) and carboplatin (AUC5; d1) every three weeks; ADR: adverse drug reaction.